Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related ...
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target Maximize Your Portfolio ...
Hosted on MSN22d
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a $484 million market cap biotech company, reported that its Chief Operating Officer, Azmi Nabulsi, sold shares of the company's common stock.
Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...
Avi Kapoor "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales ...
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...
Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results